基本信息
浏览量:77
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Experienced pharmaceutical development and outcomes research professional, skilled in driving organic growth by converting innovative ideas to drug product based on disease burden, funding flows, and legislation landscape, with expertise in pharmaceutical R&D, regulatory affairs, and HEOR.
• Invented 2 nanomedicine platforms and secured $10M internal and external funding for 2 ongoing Phase I Clinical Trials
• Skilled in conducting HEOR with a focus on utilizing RWE for cost-effectiveness and budget impact analysis
• Led 5 FDA submissions (2 IND, 1 NDA, and 2 ANDA), and 2 Phase I Clinical Trials planning
• Broad knowledge in biology/pharmaceutical sciences principles, US healthcare ecosystem, and FDA compliance
• Proven track record of publication (36 peer-reviewed papers, Impact Factor > 300, total citation > 5000)
• Invented 2 nanomedicine platforms and secured $10M internal and external funding for 2 ongoing Phase I Clinical Trials
• Skilled in conducting HEOR with a focus on utilizing RWE for cost-effectiveness and budget impact analysis
• Led 5 FDA submissions (2 IND, 1 NDA, and 2 ANDA), and 2 Phase I Clinical Trials planning
• Broad knowledge in biology/pharmaceutical sciences principles, US healthcare ecosystem, and FDA compliance
• Proven track record of publication (36 peer-reviewed papers, Impact Factor > 300, total citation > 5000)
研究兴趣
论文共 42 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Current opinion in chemical biology (2021): 143-153
MOLECULAR THERAPYno. 7 (2017): 1588-1595
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn